About Bruce

A successful pharmaceutical executive with nearly 35 years of industry experience, Bruce Eaton serves as the president and chief executive officer of i2 Pharmaceuticals, Inc. In his leadership role with i2 Pharmaceuticals, he looks to expand the company‚Äôs intellectual property holdings, which include a broad range of early and late stage pharmaceutical assets. Through a… Continue Reading

Immune Activation Advances Hold Promise for Immuno-Oncology

Immune Activation Advances Hold Promise for Immuno-Oncology

Immuno-oncology has largely changed the landscape of cancer care, but a number of challenges still exist. From judging efficacy to understanding why some people react to the treatment while others do not, researchers are tackling a number of issues. One young startup in Europe is attempting to address the latter question. At present, only about… Continue Reading

Scientists Consider Using New Animal Models for Immuno-Oncology Research

Scientists Consider Using New Animal Models for Immuno-Oncology Research

Oncological researchers face a major hurdle in trying to model the complexity of the disease, which has led to genetically engineered rats and, most recently, humanized rat models for use in preclinical studies. Scientists have achieved this unique humanized model using a range of genetic engineering technologies, including transcription activator-like effector nucleases (TALENs) and clustered… Continue Reading

What You Need to Know about Genetic Engineering and Cancer Immunotherapy

What You Need to Know about Genetic Engineering and Cancer Immunotherapy

The biomedical world was revolutionized by the introduction of clustered regularly interspaced short palindromic repeats (CRISPR) gene-editing technology, which may soon have cancer immunotherapeutic applications. Human trials of the technology are drawing nearer, as an advisory committee at the National Institutes of Health recently approved a proposal that would use CRISPR-Cas9 to bolster cancer immunotherapies… Continue Reading